BioNTech
Headquarters in Mainz | |
| Type | Public company |
|---|---|
| Nasdaq: BNTX | |
| ISIN | US09075V1026 |
| Industry | Biotechnology |
| Founded | 2008 |
| Founders |
|
| Headquarters | , Germany |
Number of locations | 26 (2026) |
Area served | Worldwide |
| Key people |
|
| Products | Pfizer-BioNTech COVID-19 vaccine, Immunotherapy and vaccine candidates |
| Services | Immunotherapy |
| Revenue | |
| Total assets | |
| Total equity | |
Number of employees | |
| Website | biontech |
| Footnotes BioNTech FY 2025 report | |
BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic.